Evidence map›Paper›PMID 31599376›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2020

Prognostic factors associated with survival in a large cohort of gastric cancer patients resected over a decade at a single Italian center: the Cremona experience.

M Ghidini, B M Donida, L Totaro, M Ratti, C Pizzo, I Benzoni, D Lomiento, F Aldighieri, L Toppo, V Ranieri and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Radiotherapy benefited the survival of patients with intestinal-type gastric adenocarcinoma: a SEER population-based study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

M GhidiniDepartment of Oncology, Operative Unit of Oncology, ASST of Cremona, Hospital of Cremona, Viale Concordia 1, 26100, Cremona, Italy. micheleghidini@outlook.com.ORCID http://orcid.org/0000-0001-5435-1218
B M DonidaDepartment of Oncology, Operative Unit of Oncology, ASST of Cremona, Hospital of Cremona, Viale Concordia 1, 26100, Cremona, Italy.
L TotaroDepartment of Surgery, Operative Unit of General Surgery, ASST of Cremona, Hospital of Cremona, Cremona, Italy.
M RattiDepartment of Oncology, Operative Unit of Oncology, ASST of Cremona, Hospital of Cremona, Viale Concordia 1, 26100, Cremona, Italy.
C PizzoDepartment of Oncology, Operative Unit of Oncology, ASST of Cremona, Hospital of Cremona, Viale Concordia 1, 26100, Cremona, Italy.
I BenzoniDepartment of Surgery, Operative Unit of General Surgery, ASST of Cremona, Hospital of Cremona, Cremona, Italy.
D LomientoDepartment of Surgery, Operative Unit of General Surgery, ASST of Cremona, Hospital of Cremona, Cremona, Italy.
F AldighieriDepartment of Surgery, Operative Unit of General Surgery, ASST of Cremona, Hospital of Cremona, Cremona, Italy.
L ToppoDepartment of Medicine, Operative Unit of Oncology, ASST of Pavia, Hospital of Voghera, Voghera, Italy.
V RanieriDepartment of Surgery, Operative Unit of General Surgery, ASST of Cremona, Hospital of Cremona, Cremona, Italy.
C SentiDepartment of Oncology, Operative Unit of Oncology, ASST of Cremona, Hospital of Cremona, Viale Concordia 1, 26100, Cremona, Italy.
G TanziDepartment of Oncology, Operative Unit of Pathology, ASST of Cremona, Hospital of Cremona, Cremona, Italy.
M MartinottiDepartment of Surgery, Operative Unit of General Surgery, ASST of Cremona, Hospital of Cremona, Cremona, Italy.
R PassalacquaDepartment of Oncology, Operative Unit of Oncology, ASST of Cremona, Hospital of Cremona, Viale Concordia 1, 26100, Cremona, Italy.
M RovattiDepartment of Surgery, Operative Unit of General Surgery, ASST of Cremona, Hospital of Cremona, Cremona, Italy.
G TomaselloDepartment of Oncology, Operative Unit of Oncology, ASST of Cremona, Hospital of Cremona, Viale Concordia 1, 26100, Cremona, Italy.
Istituti Ospitalieri di Cremona · ITOspedale Civile di Voghera · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIncidence of gastric cancer (GC) shows different distribution in Italy, with higher incidence in the north and center. We retrospectively analyzed the clinical data of patients resected at the Hospital of Cremona between January 2007 and December 2016. Available clinical variables were linked with survival to identify possible prognostic factors. MATERIALS AND

methodsVariables analyzed were age, sex, type of surgery, site, histology, invasion, nodal status, resection margins, grade, HER2 status, Helicobacter pylori infection (neo)adjuvant chemotherapy, adjuvant chemoradiotherapy, neutrophil-to-lymphocyte ratio, number of nodes removed and type of lymphadenectomy. Overall survival (OS) was estimated by the Kaplan-Meier method and differences between groups by the log-rank test. Data on OS were analyzed by Cox regression and the final model was obtained using the step-wise method.

results379 patients were considered, out of which 195 were operated from 2007 to 2011 and 184 from 2012 to 2016. Median follow-up was 25.5 months, median OS 31.3 months and time to recurrence 23.2 months. D2 resection rate increased from 36% (period 2007-2011) to 74% in 2012-2016 (p = 0.01) with a higher mean number of nodes collected (20.98 for 2007-2011 and 23.53 for 2012-2016, p = 0.040). Only 37% of patients received a postoperative treatment. At multivariate analysis, variables associated with OS were age (p = 0.002), stage (p < 0.001), resection margins status (p < 0.001), adjuvant chemotherapy (p < 0.010) and tumor location (cardia vs non-cardia) (p = 0.029).

conclusionsOur analysis shows that completeness of resection and lower stage are strong predictors of long-term survival in GC, providing the rationale for adjuvant and neoadjuvant approaches (chemotherapy, radiotherapy or combined). Cardial GC has worse prognosis compared to distal cancers. TRIAL REGISTRATION NUMBER: Service evaluation number 256, protocol 16821/17, date 05 June 2017.

Indexed as

Chemoradiotherapy, AdjuvantNeoadjuvant TherapyAdenocarcinomaAdultAgedAged, 80 and overCohort StudiesErb-b2 Receptor Tyrosine KinasesFemaleGastrectomyGene AmplificationHelicobacter InfectionsHumansItalyKaplan-Meier EstimateLymph Node ExcisionERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesGastric adenocarcinomaGastric cancerLymphadenectomySurgery

Identifiers

PMID31599376
OpenAlexW2979309338

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.